1,721,004 research outputs found
Aromatase Inhibitors in the Treatment of Endometriosis
No full textCurrent treatment of endometriosis is mainly based on surgery and ovarian suppressive agents. In the last 10 years, it has been demonstrated that aromatase P450, a key enzyme for estrogen biosynthesis, may have a pathogenic role in endometriosis because it is aberrantly expressed in endometriotic implants and in eutopic endometrium of women with endometriosis. Therefore, inhibition of aromatase activity may represent a new therapeutic option for endometriosis. Case reports and observational studies have shown that pain symptoms caused by endometriosis quickly improve after administration of aromatase inhibitors. Limited data are available on the long-term course of pain symptoms after completion of treatment with aromatase inhibitors; however, some recent studies suggest that symptoms may recur at short-term follow-up. A range of results are reported on the effects of aromatase inhibitors on endometriotic lesions, with some authors describing improvements and other authors reporting persistence of pelvic lesions at second-look laparoscopy after treatment. No severe adverse effect has been reported during treatment with aromatase inhibitors both in pre- and postmenopausal women. On the basis of the available data, administration of aromatase inhibitors should now be offered only to the small number of women who have severe pain despite previous surgical and hormonal therapies. Further research in the form of randomized controlled trials will be required before recommending the routine use of these agents
ADMINISTRATION OF PURE FOLLICLE-STIMULATING-HORMONE DURING GONADOTROPIN-RELEASING HORMONE AGONIST THERAPY IN PATIENTS WITH CLOMIPHENE-RESISTANT POLYCYSTIC OVARIAN DISEASE - HORMONAL EVALUATIONS AND CLINICAL PERSPECTIVES
No full text[Active pharmacologic monitoring of oral contraceptives. The Italian experience]
No full textThe Active Drug Monitoring project aims to assess the positive and negative effects of drugs following commercialisation. It was decided to use a study on "series of cases" in women who were taking an oral contraceptive containing 0.075 mg of Gestodene and 0.030 mg of Ethynylestradiol (Ginoden, Schering; Minulet, Wyeth). Twenty-seven centres took part in the study. 1166 women were recruited with a total of 10320 cycles studied. A data base was set up on a PC which was then used by each participating centre. Data were transmitted from the various centres using floppy disks. On enrollment a detailed medical history was recorded and, in addition to a careful objective examination, a blood sample was taken to assess biochemical parameters. The monitoring protocol consisted in the assessment of biochemical parameters at the start and end of treatment (12 months), as well as blood pressure, weight and menstrual characteristics after 3, 6 and 12 months. At each visit patients were questioned about the possible onset of collateral effects and their intensity. At the end of the study a reduction was noted in the mean cycle length (29.34 vs 27.45 days) and a parallel reduction in the quantity of menstruation. In spite of an increase in all the biochemical parameters examined, only HDL-cholesterol was statistically significant (p less than 0.01). 122 women decided not to complete the study, but only 72 due to side effects. It is however interesting to note that this decision was usually not related to the severity of symptoms
Use of combined exogenous gonadotropins and pulsatile gonadotropin-releasing hormone in patients with polycystic ovarian disease: a new approach to induction of ovulation
No full textProteomics technologies in endometriosis
No full textEndometriosis is a common disorder that is associated with infertility and pelvic pain. Diagnosis is based on the visualization of endometriotic lesions during surgery as no reliable serum marker is currently available. The etiology of endometriosis is largely unknown. Over the last 20 years, several proteomics technologies have been used to research novel proteins with a potential etiological role in endometriosis, and to identify candidate serum markers for this condition. While some molecules identified by proteomics technologies may have a relevant role in the pathogenesis of endometriosis, the research of potential serum markers for this condition is still far from any clinical application. This review summarizes the state of the art and potential applications of proteomics in endometriosis research
Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study
No full textObjective: To compare the efficacy of norethisterone acetate (NETA; group N) or letrozole combined with NETA (group L) in treating endometriotic ovarian cysts.
Study design: This patient-preference study included 20 patients in group N and 20 patients in group L. The primary aim of the study was to compare the volume of the endometriomas during and after treatment. The secondary outcome was the evaluation of the changes in pain symptoms during and after treatment.
Results: After six months of treatment, the volume of the endometriomas significantly decreased compared with baseline in both study groups; it was smaller in group L than in group N (p = 0.026). The rate of satisfied patients at six months of treatment was similar between the study groups (p = 0.451). No significant difference was reported between the two study groups in the amelioration of pain symptoms and in the incidence of adverse events.
Conclusions: LetrozolecombinedwithNETAismoreefficaciousthanNETAaloneinreducingthevolume of endometriotic cysts but in none of the 40 patients included in the study did the endometriomas disappear. The efficacy of aromatase inhibitors, however, should be balanced with the need to administer long-term treatment
CHANGES IN THE SIZE OF RECTOVAGINAL ENDOMETRIOTIC NODULES INFILTRATING THE RECTUM DURING HORMONAL THERAPIES
No full textVAGINAL DANAZOL IN WOMEN WITH RECTOVAGINAL ENDOMETRIOSIS AND PAIN SYMPTOMS PERSISTING AFTER THE INSERTION OF THE LEVONORGESTREL-RELEASING INTRA-UTERINE DEVICE
No full text- …
